Inhibiting SARS‐CoV‐2 infection with lysosomal alkalizers

Understanding the SARS‐CoV‐2 virus’ routes of infection, virus–host–protein interactions, and mechanisms of virus‐induced cytopathic effects will greatly aid in the discovery and design of new therapeutics to treat COVID‐19. Chloroquine and hydroxychloroquine, extensively explored as clinical agents...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:FASEB J
Autors principals: Gorshkov, Kirill, Chen, Catherine, Bostwick, Robert, Rasmussen, Lynn, Tran, Bruce, Cheng, Yu‐Shan, Xu, Miao, Pradhan, Manisha, Henderson, Mark, Zhu, Wei, Oh, Eunkeu, Susumu, Kimihiro, Wolak, Mason, Shamim, Khalida, Huang, Wenwei, Hu, Xin, Shen, Min, Klumpp‐Thomas, Carleen, Itkin, Zina, Shinn, Paul, de la Torre, Juan Carlos, Simeonov, Anton, Michael, Samuel, Hall, Matthew, Lo, Donald, Zheng, Wei
Format: Artigo
Idioma:Inglês
Publicat: The Federation of American Societies for Experimental Biology 2021
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239884/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fasebj.2021.35.S1.02122
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars